Zeman Merissa N, Scott Peter Jh
Department of Radiology, University of Michigan Medical School Ann Arbor, MI, USA.
Am J Nucl Med Mol Imaging. 2012;2(2):174-220. Epub 2012 Mar 28.
As remission has now become a realistic therapeutic goal in the clinical management of RA due to the introduction and widespread adoption of biologic agents, there is a greater need for earlier diagnoses and objective methods for evaluating disease activity and response to treatment. In this capacity, advanced imaging strategies are assuming an expansive clinical role, particularly as they take advantage of newer imaging technologies and the shift toward imaging at the molecular level. Molecular imaging utilizes target-specific probes to non-invasively visualize molecular, cellular, and physiological perturbations in response to the underlying pathology. Probes for nuclear and MR imaging have been and are being developed that react with discrete aspects of inflammatory and destructive pathways specific to RA. These probes in addition to new MR sequences and contrast agents have the potential to provide an earlier and more reliable assessment of clinical outcome, disease activity, severity, and location, and therapeutic response. Furthermore, these imaging strategies may enable a more fundamental understanding of critical pathophysiological processes and the advent of new molecular therapies. This review will discuss these advances in both nuclear medicine and MRI strategies for imaging RA with a particular emphasis on molecular imaging.
由于生物制剂的引入和广泛应用,缓解现已成为类风湿关节炎(RA)临床管理中的一个切实可行的治疗目标,因此更需要早期诊断以及评估疾病活动和治疗反应的客观方法。在这方面,先进的成像策略正发挥着越来越广泛的临床作用,特别是因为它们利用了更新的成像技术以及向分子水平成像的转变。分子成像利用靶向特异性探针来无创地可视化因潜在病理而产生的分子、细胞和生理扰动。用于核成像和磁共振成像(MR)的探针已经并且正在被开发出来,它们能与RA特有的炎症和破坏途径的不同方面发生反应。这些探针连同新的MR序列和造影剂有潜力对临床结果、疾病活动、严重程度和位置以及治疗反应提供更早且更可靠的评估。此外,这些成像策略可能使人们对关键的病理生理过程有更深入的理解,并推动新分子疗法的出现。本综述将讨论核医学和MRI成像RA的这些进展,特别强调分子成像。